Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia
Unknown status
National Center for Research Resources (NCRR)
Phase 1
1969-12-31
This study is to determine whether a compound, nitric oxide, made within the body, is the
factor responsible for the changes in blood pressure and renal (kidney) functions that may
occur during the course of cirrhosis. Patients with cirrhosis (liver scarring which causes
poor liver function) will be eligible to participate. A group of healthy subjects will also
be studied to compare the effects of the treatment to patients with cirrhosis and to confirm
safety. A total number of 30 patients with cirrhosis and 10 healthy subjects will be enrolled
in the study.
The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Completed
Novartis
Phase 2/Phase 3
2005-10-01
We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are
mediated in part by diminished circulatory volume and that treatment with midodrine,
octreotide and albumin can improve renal and patient outcomes by restoring effective
circulating volume and systemic perfusion.
Our primary objective is to assess change in creatinine clearance using inulin. We will
enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and
exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR,
albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before,
during, and after initiation of drug and compared.
The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Completed
University of Alberta
Phase 2/Phase 3
2005-10-01
We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are
mediated in part by diminished circulatory volume and that treatment with midodrine,
octreotide and albumin can improve renal and patient outcomes by restoring effective
circulating volume and systemic perfusion.
Our primary objective is to assess change in creatinine clearance using inulin. We will
enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and
exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR,
albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before,
during, and after initiation of drug and compared.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
